Dosimetric consequences of increased seed strength for I-125 prostate implants.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 13129638.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Based on the findings of an earlier planning study, we compared post-implant dose distributions for two groups of 20 consecutive patients treated to 145 Gy with 0.414 and 0.526 U I-125 seeds. Dosimetric coverage as measured by the key clinical index D(90) was significantly better for the higher-strength seeds, with no apparent deleterious effects.
Medical subject headings
- Iodine Radioisotopes
- Prostatic Neoplasms
- Radiotherapy Planning, Computer-Assisted